A new study published in BMC Pediatrics argues that much of this bewildering heterogeneity stems from a factor that has never been systematically examined: patient selection. The research team, led by pediatric cardiologists and cardiac surgeons at Koç University Hospital in Istanbul, proposes a fully preoperative, mechanism-anchored framework designed to identify which children with severe functional mitral regurgitation are most likely to benefit from valve repair rather than proceeding directly to transplantation or mechanical circulatory support. The authors emphasize that the framework is a proof-of-concept clinical hypothesis, not a validated decision algorithm, and that prospective multicenter validation is required before any clinical adoption.

The framework classifies candidates into three categories defined a priori. Children are labeled Non-MR-dominant if any of four affirmative features are documented: a toxic, storage, infiltrative, or myopathic underlying etiology; primary structural disease of the mitral valve itself; preoperative irreversible end-organ failure or extracorporeal membrane oxygenation with multi-organ dysfunction; or severe right ventricular dysfunction, fixed pulmonary hypertension, or severe tricuspid regurgitation arising from right ventricular and annular dilatation. The logic is that in these patients, the leaking mitral valve is a downstream symptom of a broader disease process that valve repair alone cannot reverse.

Conversely, patients without any of those features who meet three volume-overload criteria are classified as MR-dominant. Those criteria are idiopathic, familial, or sarcomeric dilated cardiomyopathy; functional mitral regurgitation of at least grade 3+; and a left ventricular end-diastolic diameter Pettersen Z-score of plus five or greater. In this group, the researchers argue, the regurgitation itself becomes the dominant driver of a vicious cycle: the leak volume-loads an already weakened ventricle, causing further dilatation, worsening leaflet coaptation, and progressively more severe regurgitation. Interrupting that cycle surgically may allow the ventricle to remodel back toward a healthier geometry.

A third category, Borderline MR-dominant, captures children who do not meet all MR-dominant criteria but satisfy one of three predefined conditions: infancy with intermediate fractional shortening; post-myocarditis status with documented regional scar or a fibrotic substrate on imaging; or a left ventricular end-diastolic diameter Pettersen Z-score between plus 3.5 and less than plus 5 accompanied by severe functional regurgitation. The borderline designation acknowledges the clinical gray zone where the mechanism is plausible but the evidence is less complete, and it places these patients in an intermediate tier rather than excluding them outright.

To test the framework, the team applied it to a single-center cohort of six consecutive children. Three MR-dominant children underwent mitral valve repair and sustained ventricular remodeling, achieving transplant-free survival at a median follow-up of thirty months, with N-terminal pro-B-type natriuretic peptide, a key blood biomarker of heart failure severity, falling by 86 to 99 percent. The other three children were not selected for repair: one MR-dominant child whose family declined surgery, and two Non-MR-dominant children. All three died. The authors are careful not to overinterpret this small observational signal, but the concordance between the framework’s predictions and the observed outcomes is the study’s central proof of concept.

The researchers then took a more ambitious step: they applied the framework, masked to outcome, to all 22 previously published pediatric patients who received mitral valve repair, pooling them with their own cohort for a combined analysis of 25 patients. Among the MR-dominant and Borderline patients, clinical stabilization and/or remodeling was achieved in 16 of 20 cases, or 80 percent. Among Non-MR-dominant patients, the corresponding figure was 1 of 5, or 20 percent. The difference was statistically significant by Fisher’s exact test, with a p-value of 0.024 and an odds ratio of 11.0 with a 95 percent confidence interval of 1.3 to 91.8.

That wide confidence interval reveals the study’s most important limitation, which the authors discuss with unusual candor. The association is statistically significant in the primary specification but is fragile to single-patient reclassification, an unavoidable consequence of the fact that only five Non-MR-dominant patients have been reported across three decades of global pediatric literature. Moving a single patient between categories could materially shift the result. This transparency is itself notable in a field where small series and selective reporting have historically inflated the apparent success of surgical techniques.

The clinical implications, if the framework survives validation, could be substantial for regions where pediatric heart transplantation and durable ventricular assist device support are inaccessible or severely limited. In MR-dominant disease, the authors suggest, mitral valve repair may support clinical stabilization with the potential for reverse remodeling, offering a viable bridging strategy or even an alternative to transplantation. The framework deliberately places the burden of proof on assigning a child to the Non-MR-dominant category, inverting the traditional default of reserving surgery for the sickest or most desperate cases.

The study received no specific external funding, was approved by the Koç University Institutional Review Board, and is published open access. The authors used generative artificial intelligence tools exclusively for language editing, stating that all scientific content, data analysis, and clinical interpretation are their own. For now, the message to the pediatric cardiology community is measured: a biologically grounded, fully preoperative framework offers a coherent interpretation of three decades of contradictory outcomes, but only prospective multicenter testing can determine whether it should guide real-world surgical decisions.

Subject of Research: A preoperative selection framework for mitral valve repair in pediatric dilated cardiomyopathy with severe functional mitral regurgitation

Article Title: Mitral valve repair for pediatric dilated cardiomyopathy with severe functional mitral regurgitation: a mechanism-anchored, proof-of-concept preoperative selection framework with supportive cohort and pooled outcomes

Article References: Kizilkaya, M. H., Cakan, B., Ardali, A., Bicer, M., Tanyildiz, M., Ozden, O., & Odemis, E. (2026). Mitral valve repair for pediatric dilated cardiomyopathy with severe functional mitral regurgitation: a mechanism-anchored, proof-of-concept preoperative selection framework with supportive cohort and pooled outcomes. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07857-5

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07857-5

Keywords: dilated cardiomyopathy, mitral valve repair, functional mitral regurgitation, pediatric heart failure, patient selection framework, ventricular remodeling, pediatric cardiac surgery, heart transplantation, NT-proBNP, BMC Pediatrics, Mitral, valve

Dilated cardiomyopathy, or DCM, is characterized by enlargement and weakening of the ventricles, and cardiac fibrosis — the excessive accumulation of extracellular matrix proteins such as collagens — is a major driver of that adverse remodeling. Fibrosis stiffens the heart wall, impairs its ability to fill with blood, and progressively worsens function. But fibrosis is not produced by a single, uniform population of cells. Cardiac fibroblasts occupy dynamic, injury-dependent transcriptional states, and single-cell and single-nucleus profiling has revealed marked stromal heterogeneity in both healthy and diseased myocardium. Activated fibroblasts can be sparse in non-failing hearts yet enriched in cardiomyopathy, and previous work has implicated the transcription factor MEOX1 as a regulator of fibroblast activation. What remained uncertain was which human DCM fibroblast state is most reproducibly enriched across cohorts, and whether its disease association is stronger than that of the conventional ACTA2-high myofibroblast state that has dominated the literature.

To answer that question, the study used a prespecified discovery-and-validation design built entirely on publicly available data. The discovery cohort, GSE183852, contained left-ventricular nuclei from 25 non-failing donor hearts and 13 DCM hearts. The external validation cohort, SCP1303, contained 16 normal and 11 DCM hearts, with hypertrophic cardiomyopathy samples excluded from the primary comparison. Fibroblasts from the discovery cohort — 49,124 nuclei in total — were independently reclustered in Seurat using log normalization, 2,500 variable features, 30 principal components, a shared-nearest-neighbor graph, and Louvain clustering at resolution 0.5, with a fixed random seed to ensure reproducibility. Critically, the author treated the donor, not the individual nucleus, as the statistical unit of inference, a decision that guards against the false discoveries that arise when thousands of nuclei from one patient are mistakenly counted as independent biological replicates.

The reclustering resolved multiple fibroblast states and revealed substantial compositional variation between donors. One cluster stood out: cluster two showed high expression of MEOX1 and FAP together with relatively low ACTA2, the gene encoding alpha-smooth muscle actin that marks the classical contractile myofibroblast. The study is careful to note that ACTA2-low is a relative property — ACTA2 was detected in 14.7 percent of cluster-two nuclei versus 57.3 percent in the discrete ACTA2-high cluster 16 — and does not imply absent expression or a lack of overall ACTA2 induction in disease. Cluster two nonetheless retained clear extracellular-matrix features, expressing FN1, POSTN, COL1A1 and COL3A1, and an unbiased marker analysis surfaced RFX2, CYR61, FOS, EGR1, DDAH1, CTGF, FAP and MEOX1 among its leading genes. The state was therefore defined by the combined three-marker pattern rather than any single gene.

The quantitative case for disease enrichment rests on donor-level proportions. Cluster two made up a median 5.81 percent of fibroblasts in DCM hearts versus 0.28 percent in donor hearts, a difference that was highly significant after false-discovery-rate correction. The mean DCM-minus-donor difference was 0.165, with a 95 percent confidence interval of 0.035 to 0.349 derived from 10,000 iterations of donor bootstrap resampling. Perhaps most tellingly, sequentially omitting each of the 38 donors one at a time never flipped the direction of the effect, which stayed within a range of 0.102 to 0.179. Sensitivity analyses across clustering resolutions showed that while the default state merged into broader compartments at lower resolutions, higher-resolution counterparts retained disease enrichment with p-values below 2 × 10⁻⁶. By contrast, the ACTA2-high cluster 16 showed only a smaller, non-significant abundance difference between groups.

Covariate modeling added nuance rather than contradiction. Heteroscedasticity-consistent HC3 linear models estimated a DCM coefficient of 0.165 unadjusted, 0.166 after adjusting for sex, and 0.184 after adjusting for both sex and ordinal age tertile — the finest age granularity the source data allowed. The effect magnitude was preserved in every model, but the confidence intervals marginally crossed zero, and the author explicitly declines to claim covariate-independent statistical significance. This kind of restraint is uncommon in reanalysis studies and reflects the modest number of donors available: with 38 hearts in the discovery cohort, even a robust effect can produce intervals that graze the null.

External validation in the independent SCP1303 cohort strengthened the finding while also defining its boundary. The author-annotated activated fibroblast population, FB-ActFB, was far more abundant in DCM than in normal hearts — a median of 24.11 percent versus 5.16 percent of fibroblasts — with a mean difference of 0.192 and a bootstrap confidence interval of 0.144 to 0.256. All 27 leave-one-donor-out estimates remained positive, and the sex-adjusted coefficient was 0.199 with a p-value of 6.61 × 10⁻⁷. The external state showed concordant MEOX1 and FAP expression, but ACTA2 was not available in the retained external marker summary, and validation relied on the source study’s annotations rather than frozen one-to-one label transfer. The author therefore concludes that the replication supports a shared activation program and abundance shift, not a complete reproduction of the three-marker phenotype or identical cellular identity.

Beyond the state itself, donor-pseudobulk differential expression — in which raw fibroblast counts are summed within each donor before testing — identified several genes elevated in DCM fibroblasts after false-discovery-rate correction. DDAH1 led the list with an adjusted log2 fold change of 2.01, followed by MEOX1 at 2.29 and FAP at 1.89; POSTN, TGFBI, CTGF and COL1A2 also passed correction. Within discovery cluster two, nuclei positive for DDAH1 showed higher extracellular-matrix scores than DDAH1-negative nuclei in paired donor summaries. DDAH1, an enzyme involved in nitric oxide metabolism, has previously been linked to cardiac hypertrophy and remodeling in animal models, which makes it a biologically plausible candidate. The study is emphatic, however, that DDAH1 is a prioritized state-associated candidate, not an established causal regulator, and it was deliberately excluded from the state-defining marker panel to avoid circularity.

The extracellular-matrix evidence itself proved partly method-dependent, a finding the author reports transparently. The donor-pseudobulk ECM score was significantly higher in DCM hearts, with a Mann–Whitney p-value of 0.00975, whereas the cell-derived donor mean showed the same positive direction without reaching significance. The two scoring approaches were nonetheless strongly correlated across donors, with a Spearman correlation of 0.891. Whole-fibroblast pseudobulk differences can reflect both shifts in state composition and expression changes within states, so they cannot by themselves establish cluster-specific regulation. ACTA2, notably, showed a modest overall increase in DCM fibroblasts, reinforcing that the ACTA2-low label describes a relative cluster phenotype rather than a claim that canonical myofibroblasts are absent from the diseased heart.

The study’s limitations are acknowledged candidly: it is a secondary analysis without spatial, protein-level or functional validation; age information was incomplete in both cohorts; reliable etiologic subdivisions of DCM were unavailable; and public-cohort processing differences precluded exact state transfer between datasets. Still, the work delivers something the field genuinely needs — a technically controlled, hypothesis-generating target for prospective experiments. The author proposes that multiplex tissue imaging should test the spatial coexistence of MEOX1, FAP, ACTA2 and DDAH1 in diseased myocardium, while fibroblast perturbation studies should determine whether DDAH1 alters collagen synthesis, matrix organization or state transitions. If those experiments pan out, a fibroblast state first glimpsed in reprocessed public data could point toward new anti-fibrotic strategies for a disease that currently has few options beyond transplantation.

Subject of Research: Identification of a disease-associated MEOX1+FAP+ACTA2-low fibroblast state in dilated cardiomyopathy using cross-cohort single-nucleus RNA sequencing

Article Title: Cross-cohort single-nucleus transcriptomic identification of a MEOX1+FAP+ACTA2-low extracellular matrix-remodeling fibroblast state in dilated cardiomyopathy

Article References: Li, Y. (2026). Cross-cohort single-nucleus transcriptomic identification of a MEOX1+FAP+ACTA2-low extracellular matrix-remodeling fibroblast state in dilated cardiomyopathy. Frontiers in Genetics, 17, Article 1987893. https://doi.org/10.3389/fgene.2026.1987893

Image Credits: AI Generated

DOI: 10.3389/fgene.2026.1987893

Keywords: dilated cardiomyopathy, cardiac fibrosis, fibroblasts, single-nucleus RNA sequencing, MEOX1, FAP, ACTA2, DDAH1, extracellular matrix, pseudobulk differential expression, biomarkers, Cross-cohort

Researchers at the Children’s Hospital of Fudan University in Shanghai analyzed 77 children with a dilated cardiomyopathy phenotype who had all undergone genetic testing at their center. The team, led by Jialing Liu, Chen Chu, and Yixiang Lin, with Huijun Wang and Fang Liu as corresponding authors, set out to map the genetic landscape of pediatric dilated cardiomyopathy in a Chinese population and, more importantly, to determine whether genetic results carry any prognostic weight. Their findings, published in BMC Pediatrics, suggest that they do.

The technical foundation of the study rests on next-generation sequencing. The children underwent clinical exome sequencing or whole-exome sequencing, approaches that read the protein-coding regions of the genome where disease-causing mutations in heart muscle genes typically hide. Every variant detected was classified according to the guidelines of the American College of Medical Genetics and Genomics, the internationally accepted framework that sorts genetic changes into categories ranging from benign to pathogenic based on evidence such as population frequency, predicted protein effects, and previous disease associations. Only variants graded as pathogenic or likely pathogenic counted toward a positive genetic result, while ambiguous variants of uncertain significance were excluded from the genotype-positive designation.

That rigorous classification matters, because the yield was meaningful but not overwhelming. Pathogenic or likely pathogenic variants were identified in 17 of the 77 children, a detection rate of 22.1 percent. The most frequently implicated genes were FLNC, LMNA, TNNT2, and TTN, a roster that will be familiar to anyone who follows cardiovascular genetics. TTN, which encodes titin, the gigantic spring-like protein that gives cardiac muscle cells their elastic recoil, is the most common gene implicated in adult dilated cardiomyopathy. LMNA, which produces the lamin proteins that scaffold the cell nucleus, is notorious for producing aggressive disease with conduction system problems and a high risk of sudden cardiac death. FLNC and TNNT2 encode filamin C and cardiac troponin T respectively, proteins central to the structural integrity and contractile machinery of the heart cell.

The study’s central result emerged when the researchers split their cohort into genotype-positive and genotype-negative groups and followed them over time. Using Kaplan-Meier survival analysis, the standard statistical method for tracking how many patients remain free of a defined event over a period, they found that children carrying disease-causing variants fared significantly worse than those without them. Among the genotype-positive children, only 64.7 percent remained free of death or cardiac transplantation at one month after diagnosis. That figure fell to 47.1 percent at one year and 35.3 percent at three years, a steep and sobering decline that underscores how unforgiving genetically driven disease can be in young patients.

To quantify the risk more precisely, the team turned to Cox proportional hazards regression, a modeling technique that estimates how a given factor changes the instantaneous risk of an event while accounting for follow-up time. In univariable analysis, genotype-positive status was associated with roughly a 2.3-fold higher risk of death or cardiac transplantation, with a hazard ratio of 2.29 and a 95 percent confidence interval of 1.06 to 4.94, reaching statistical significance at a P value of 0.035. When the investigators adjusted the model for age at diagnosis and New York Heart Association functional class, a clinical measure of heart failure severity, the association weakened and no longer reached the conventional threshold for significance, yielding a hazard ratio of 2.10 with a confidence interval of 0.97 to 4.55 and a P value of 0.060.

That attenuation is worth examining carefully, because it illustrates a perennial tension in clinical research. The adjusted analysis suggests that some of the apparent genetic risk may overlap with how sick children already appear at diagnosis, since older age and worse functional class are themselves markers of advanced disease. Yet a hazard ratio hovering just above 2 with a confidence interval that barely crosses 1.0 is hardly evidence of no effect; with only 17 genotype-positive patients, the study was almost certainly underpowered to fully separate genetic risk from clinical severity. The authors themselves frame the conclusion conservatively, stating that genotype-positive patients showed poorer event-free survival and that genetic evaluation may provide useful information for prognostic assessment rather than claiming genetics independently predicts outcome.

Why does this matter for clinical practice? Pediatric dilated cardiomyopathy is rare and genetically heterogeneous, and its management has long been dominated by phenotype: echocardiographic measurements of left ventricular size and ejection fraction, biomarkers such as NT-proBNP and cardiac troponin I, and functional classification. The study’s abbreviation list hints at the full diagnostic arsenal, from cardiac magnetic resonance imaging with late gadolinium enhancement to detailed volumetric indices of ventricular remodeling. Genetic testing has been creeping into routine care, but its role has often been justified on diagnostic and family-screening grounds alone. Demonstrating that a positive genotype tracks with worse event-free survival gives clinicians a second, prognostic reason to order the test, potentially supporting earlier escalation of therapy, closer surveillance, or timely referral for advanced options such as mechanical circulatory support or transplantation evaluation.

The family dimension is equally consequential. Identifying a pathogenic variant in a child with dilated cardiomyopathy converts an isolated case into a heritable condition, opening the door to cascade testing of parents and siblings. Because many of the implicated genes act in an autosomal dominant fashion, a parent may carry the same variant, sometimes with subtle or undiagnosed cardiac involvement, and other relatives may harbor the mutation before any symptoms appear. In diseases where early detection can change the trajectory, that knowledge is not academic. It is also why the 22.1 percent detection rate, while lower than some figures reported in adult cohorts, still represents a substantial fraction of children whose families can now receive targeted genetic counseling.

Like all retrospective single-center studies, this work has limits the authors acknowledge implicitly through their design. The cohort was modest, testing was performed at one tertiary Chinese center that may see disproportionately severe cases, and the genetic technologies used, focused as they are on exomes, can miss variants in non-coding regions, structural rearrangements, or copy number changes that newer genome sequencing approaches would capture. The genotype-negative group may also contain children with variants that current knowledge cannot yet classify as pathogenic. Still, the study fills a genuine gap, since the genetic spectrum and prognostic significance of dilated cardiomyopathy in Chinese children had remained incompletely characterized. As sequencing costs continue to fall and variant databases grow more diverse, the hope is that genetic testing will move from an optional add-on to a standard pillar of pediatric cardiomyopathy care, helping clinicians decide not only what a child’s heart is doing today, but what it is likely to do tomorrow.

Subject of Research: Genetic testing and prognosis in pediatric dilated cardiomyopathy

Article Title: Clinical characteristics, genetic findings, and outcomes in 77 Chinese children with dilated cardiomyopathy who underwent genetic testing: a retrospective study

Article References: Liu, J., Chu, C., Lin, Y., Wang, F., He, L., Zhao, Q., Zhao, L., Sun, S., Zheng, Y., Wang, J., Chen, W., Yan, G., Zhang, Z., Wang, H., & Liu, F. (2026). Clinical characteristics, genetic findings, and outcomes in 77 Chinese children with dilated cardiomyopathy who underwent genetic testing: a retrospective study. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07793-4

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07793-4

Keywords: dilated cardiomyopathy, pediatric cardiology, genetic testing, FLNC, LMNA, TNNT2, TTN, event-free survival, Kaplan-Meier analysis, Cox regression, ACMG variant classification, heart failure

The patient arrived with a formidable list of problems. He had long-standing dilated cardiomyopathy, a condition in which the heart muscle stretches and weakens until it can no longer pump effectively. He also carried a cardiac resynchronization therapy defibrillator, a device implanted under the skin with wires, or leads, running through veins directly into the heart. That device had become infected. Blood tests revealed methicillin-sensitive Staphylococcus aureus, a virulent bacterium circulating in his bloodstream, and the pocket of tissue housing the generator was itself infected. He was in respiratory failure, his kidneys were shutting down, and his clinical picture was consistent with mixed septic and cardiogenic shock, a combination of infection-driven and pump-failure-driven collapse that carries a grave prognosis.

Transthoracic echocardiography, an ultrasound scan of the heart, showed just how precarious his situation was. The left ventricle, the main pumping chamber, was severely dilated, and its ejection fraction, the fraction of blood expelled with each beat, was a mere 10 percent. A healthy heart ejects roughly 55 to 70 percent. At 10 percent, the chamber was functioning at a level at which even minor procedural stress can trigger irreversible collapse. The defibrillator lead, moreover, had been in place for 17 years. Older leads bind to the vessel walls and heart tissue with dense fibrous scar, and extracting them in a patient with such profound ventricular dysfunction was judged to be extremely high risk.

The standard of care for cardiac device-related infective endocarditis is unambiguous: complete removal of all implanted hardware, because leaving any infected foreign material behind allows the infection to persist and relapse. International consensus documents from the European Heart Rhythm Association and the American Heart Association both emphasize that incomplete extraction is associated with recurrent infection and worse outcomes. Yet the same guidelines acknowledge the central paradox that the Japanese team confronted. Transvenous lead extraction, in which the leads are freed from scar tissue and pulled out through the veins, can cause major cardiac and vascular complications, and patients in shock tolerate those complications poorly. Registry data from the ESC-EHRA ELECTRa collaboration have documented that major complications after transvenous lead extraction are rare but often catastrophic, particularly in fragile patients.

The team’s solution was to buy hemodynamic insurance before touching anything. They implanted an Impella 5.5, a microaxial flow pump roughly the width of a pencil, through the right subclavian artery, the vessel running beneath the collarbone that gives access to the axillary region referenced in the report’s title. The Impella 5.5 is a catheter-mounted rotor that spans the aortic valve and continuously draws blood out of the left ventricle, propelling it into the ascending aorta. Unlike older temporary pumps, the 5.5 can deliver up to about 5.5 liters of flow per minute, close to the entire output of a healthy heart at rest, and it is designed for support lasting weeks rather than hours. In this patient, it effectively took over the work of a ventricle that could barely function, providing forward flow independent of the diseased muscle.

With the pump running, the surgeons performed the first stage of source control: surgical drainage of the infected generator pocket. This initial step reduced the bacterial burden at the most accessible site of infection without subjecting the heart to the traction forces of lead removal. Only after the patient had stabilized on the pump, and after his requirement for vasoactive drugs, the powerful medications used to constrict blood vessels and maintain blood pressure in shock, had fallen, did the team proceed to the definitive procedure. On hospital day 6, they extracted all of the leads transvenously, with the Impella 5.5 still providing full circulatory support and a cardiovascular surgical team standing by as backup.

The extraction itself illustrated precisely why the pump had been worth the trouble. As the surgeons applied traction to the 17-year-old defibrillator lead, the pulmonary artery pressure transiently decreased, a sign that the mechanical stress of freeing the lead was disturbing cardiac function. In an unsupported patient with a 10 percent ejection fraction, such a perturbation could have cascaded into systemic collapse. Here, it did not. Sustained hemodynamic collapse never occurred, because the microaxial pump maintained perfusion to the brain, kidneys, and other vital organs throughout the procedure. The pump acted as a hemodynamic shock absorber, smoothing over the transient insults that lead extraction inevitably inflicts on a failing heart.

The recovery that followed was equally instructive. The patient received a prolonged course of intravenous antibiotics, the standard treatment once all infected hardware has been removed and the bloodstream has been sterilized. Blood cultures remained negative, confirming that the bacteremia had been eradicated. His kidneys recovered sufficiently that continuous hemodiafiltration, a form of around-the-clock renal replacement therapy used in critically ill patients, could be discontinued. This end-organ recovery is not a trivial footnote; it is often the deciding factor in whether a patient can ever qualify for advanced therapies. Once he was stable and infection-free, he was transferred to an advanced heart failure center, where surgeons successfully implanted a durable left ventricular assist device, an implanted pump designed to support the failing heart for years.

The case report thus describes what the authors call a bridge-to-bridge strategy: a temporary pump that stabilizes a patient through the acute infectious crisis, enabling staged source control and high-risk lead extraction, and then sustains end-organ recovery long enough for the patient to become a candidate for durable mechanical circulatory support. The Impella 5.5 has an expanding evidence base for extended support, with prior studies documenting support durations beyond 50 days as a bridge to heart transplantation and analyzing outcomes of extended support including transitions to extracorporeal membrane oxygenation. What this report adds is a specific new indication: using axillary Impella support not primarily for cardiogenic shock from a heart attack, the setting in which microaxial pumps have been most intensively studied in recent randomized trials, but as a platform for infection control in device-related endocarditis complicated by end-stage heart failure.

The authors are careful to frame this as a single-patient experience, and the report itself notes that the approach may be appropriate for carefully selected patients rather than as a universal strategy. Microaxial pump support carries its own risks, including vascular complications at the access site, hemolysis, and bleeding, and prolonged support demands intensive surveillance. Sepsis-induced cardiomyopathy, in which infection itself further depresses heart function, adds another layer of complexity to cases like this one. Still, the trajectory of this patient, from mixed septic and cardiogenic shock with multi-organ failure to successful durable left ventricular assist device implantation, demonstrates a principle that is likely to influence how such cases are managed going forward. When the cure for an infection requires a procedure the heart cannot tolerate, temporarily replacing the heart’s work may be the step that makes the cure possible. For clinicians confronting the growing population of patients with infected cardiac devices and failing ventricles, this case provides a concrete, technically detailed template for doing exactly that.

Subject of Research: Axillary Impella 5.5 mechanical circulatory support as a bridge through staged source control and lead extraction in cardiac device-related infective endocarditis with end-stage heart failure

Article Title: Axillary microaxial flow pump support for stepwise source control and bridge to durable left ventricular assist device therapy in cardiac device–related infective endocarditis

Article References: Tamura, Y., Nakahara, S., Saito, M., Torikai, K., Toda, K., & Taguchi, I. (2026). Axillary microaxial flow pump support for stepwise source control and bridge to durable left ventricular assist device therapy in cardiac device–related infective endocarditis. Journal of Artificial Organs, 29(4), Article 68. https://doi.org/10.1007/s10047-026-01599-y

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01599-y

Keywords: Impella 5.5, cardiac device-related infective endocarditis, transvenous lead extraction, mechanical circulatory support, dilated cardiomyopathy, left ventricular assist device, cardiogenic shock, Staphylococcus aureus, source control, cardiac resynchronization therapy defibrillator, microaxial flow pump, heart failure

The controversy began in earnest during the 2010s, when grain-free formulations exploded across the American pet food market. Sales at one boutique retail chain tripled between 2011 and 2015, and by 2019 grain-free products accounted for 43 percent of all extruded diets sold there. By 2017, diets built on peas, chickpeas, lentils, sweet potatoes and tapioca made up more than half of the dog food market. When the FDA announced its investigation the following year, it triggered a wave of research across academia and industry, spanning randomized controlled trials and observational studies in both client-owned and research colony dogs. Yet although that body of work focused narrowly on dilated cardiomyopathy, many individual veterinarians began broadly advising owners to avoid grain-free diets for any cardiac concern, including murmurs and mitral valve disease, and even for breeds predisposed to heart disease, purely out of caution.

A central weakness in this literature has long been its reliance on owner-reported diet histories. Previous studies repeatedly identified owner recall of primary diet type, treats, supplements and other food items as a substantial methodological limitation, with reports of grain-free status frequently overestimated, misattributed or incomplete. The new analysis, led by researchers affiliated with the Dog Aging Project, set out to quantify exactly how inaccurate owner reporting of grain-free status actually is, and then to determine whether that inaccuracy could distort the apparent relationship between diet and heart disease in a large longitudinal cohort. The DAP follows more than 50,000 companion dogs of all breeds and ages, collecting annual data on health, lifestyle and environmental factors that influence canine longevity.

To validate owner reports, the team took advantage of a natural experiment within the survey structure. From January 2020 to June 2023, the DAP’s original diet survey asked owners a simple yes-or-no question about whether their dog’s primary diet was grain-free. In July 2023, a far more comprehensive questionnaire was introduced, asking for the full brand name and formula of the diet, along with how long it had been fed. Owners who reported feeding the same diet for at least twelve months could therefore be assessed twice: once by their own grain-free label, and once by independent verification. A coder individually checked 13,049 such responses against online ingredient lists, classifying any diet containing rice, corn, wheat, barley or oats as grain-inclusive.

The validation revealed striking misclassification. Thirty-five percent of owners reported feeding grain-free diets, yet when a grain-free claim was made, it was correct only 49 percent of the time, essentially a coin flip. By contrast, owners who reported grain-inclusive diets were far more reliable, with a negative predictive value of 92 percent, and overall accuracy across all reports was 77 percent. The researchers suspect naming conventions drive much of the error: diets with titles such as a meat-and-potato recipe, which carry no grain in the name but contain grains in the ingredient list, were frequently mislabeled as grain-free by owners who judged by packaging rather than ingredients.

Crucially, the team did not stop at documenting the error. They ran simulation studies with synthetic populations of 10,000 dogs, introducing reporting inaccuracy rates of 25, 50 and 75 percent across a range of hypothetical true effect sizes, from protective to severely harmful. The simulations demonstrated that this particular pattern of misclassification, in which grain-free diets are inconsistently reported while grain-inclusive diets are reliably reported, would attenuate true associations, pulling observed odds ratios toward 1, but would not create false associations or reverse their direction. In other words, if grain-free diets truly caused heart disease, the analysis should still have detected a harmful trend, merely a weakened one. Based on the degree of attenuation observed, the researchers estimated that their measured odds ratio of 1.05 corresponds to a true odds ratio of roughly 1.07, a negligible effect.

The longitudinal analysis itself drew on the first three years of DAP diet data, covering 47,444 dogs enrolled before the end of 2023, including 7,786 dogs whose owners completed an end-of-life survey capturing diagnoses reported after the last annual follow-up. Confounders were identified using a directed acyclic graph, a formal causal inference tool, rather than ad hoc selection. The unadjusted odds ratio for grain-free diet on new cardiac diagnoses was 0.98, with a p value of 0.56. After adjusting for breed status, sex, neuter status, body size and survey year, the adjusted odds ratio was 1.05, with a confidence interval spanning 0.91 to 1.21 and a p value of 0.52. Mixed-effects models and a diet-switching analysis produced consistent results. Across every modelling approach, grain-free diet status showed no effect on the risk of incident cardiac disease.

What did matter were other factors. Single-breed dogs were more likely than mixed-breed dogs to receive new cardiac diagnoses, with an odds ratio of 1.23, and neutered animals were diagnosed substantially more often than intact ones, with an odds ratio of 1.68, the strongest association in the model. Larger dogs showed smaller odds ratios, and diagnoses became more common in later survey years. The researchers argue that neuter status, which may reflect biological protection from sex hormones or simply longer lifespans and greater time at risk, deserves far more attention in future diet and cardiac research, noting that previous studies may have been affected by failing to account for it.

The most common diagnoses in the cohort were murmurs, accounting for 57 percent of reported cardiac conditions, followed by congestive heart failure, valve disease and arrhythmia, each around 8 to 9 percent. Because murmurs and valve disease dominate the cardiac burden in companion dogs, the findings are particularly relevant to practitioners who have been advising owners to transition dogs with valve disease away from grain-free diets as a precaution. The authors caution, however, that the study was not designed to detect effects on individual cardiac diseases, nor does it examine whether diet influences survival after a diagnosis, questions that ongoing work aims to address.

Important limitations remain. The original DAP diet survey did not capture individual ingredients, so the analysis cannot speak to specific components such as peas, lentils or potatoes, which prior research has flagged as potential concerns when fed in high proportions, possibly through impaired amino acid digestibility and taurine status. Moreover, the data collection period of 2020 to 2023 coincides with years of intense public scrutiny, during which many manufacturers may have reformulated grain-free products to remove suspect ingredients. If industry reformulation has already addressed the problem, the absence of an association in this cohort may reflect safer formulations rather than proof that all grain-free diets were always harmless. The team also notes possible recall bias regarding diet duration and the possibility that diets were reformulated between the time they were fed and the time their ingredients were verified in 2025.

Even with those caveats, the study’s strengths are considerable: prospective data collection, three years of dietary exposure, inclusion of dogs that died during the study window, confounder selection guided by formal causal tools, and consistency across multiple analytical methods. The conclusion is preliminarily reassuring for the millions of dog owners who have worried, or been warned, that grain-free kibble might be silently damaging their pet’s heart. At the population level, grain-free status appears to have no effect on new cardiac diagnoses, and the imperfections in owner reporting, while real, were of a kind that could only have masked a true effect, not invented a clean bill of health. As the researchers emphasize, considerably more research is needed to determine whether specific ingredients affect specific cardiac diseases, but the blanket avoidance of all grain-free diets now lacks support from the largest longitudinal dataset yet brought to bear on the question.

Subject of Research: The relationship between grain-free diets and new cardiac diagnoses in companion dogs, and the accuracy of owner-reported diet data, in the Dog Aging Project cohort.

Article Title: Multiple Modelling Methods Suggest That Grain‐Free Diets Are Not Predictive of New Owner‐Reported Cardiac Diagnoses Over Two Years in the Dog Aging Project, Despite Owner Misclassification of Diet

Article References: O'Brien, J., Bishop, M., Dog Aging Project Consortium, Tolbert, M. K., & Ruple, A. (2026). Multiple Modelling Methods Suggest That Grain‐Free Diets Are Not Predictive of New Owner‐Reported Cardiac Diagnoses Over Two Years in the Dog Aging Project, Despite Owner Misclassification of Diet. Veterinary Medicine and Science, 12(5), Article e71213. https://doi.org/10.1002/vms3.71213

Image Credits: AI Generated

DOI: 10.1002/vms3.71213

Keywords: grain-free diets, canine cardiac disease, Dog Aging Project, dilated cardiomyopathy, diet misclassification, owner-reported data, veterinary nutrition, longitudinal study, logistic regression, causal inference, dog health, FDA investigation

The clinical story began long before the emergency that defined it. The boy was born at full term with a normal birth weight of 2608 grams, but by two months of age he was hospitalized for poor weight gain and declining cardiac function. Oral medications stabilized him enough for discharge after a two-month stay. Genetic testing eventually revealed a nonsense mutation, designated c.153C > G, in the TAZ gene, the molecular signature of Barth syndrome. This X-linked recessive condition arises from defects in an enzyme that remodels cardiolipin, a phospholipid essential to the structure and function of mitochondria, the energy-producing structures inside cells. The result is a constellation of problems: dilated cardiomyopathy in which the heart muscle stretches and weakens, generalized muscular hypotonia, and cyclical neutropenia that leaves patients vulnerable to infection. When the child was readmitted at one year of age with severe cardiac dysfunction and a brain natriuretic peptide level of 2096 pg/mL, a marker of profound heart strain, inotropic drugs failed to rescue him and he was transferred to Osaka for transplant registration and placement of a Berlin Heart EXCOR, the only durable ventricular assist device approved for small children in Japan.

His condition deteriorated faster than the transplant system could move. On admission he weighed just 6.1 kilograms and measured 67.5 centimeters. Echocardiography showed a left ventricle dilated to 38 millimeters, a z-score of +5.7 relative to normal body size, an ejection fraction of only 15 percent, and severe mitral regurgitation; his BNP had surged to 7667 pg/mL. Soon after arrival he developed runs of non-sustained ventricular tachycardia, a dangerous rhythm disturbance, and amiodarone therapy dropped his blood pressure. The team established venoarterial extracorporeal membrane oxygenation through neck vessels as an emergency salvage measure, but acute pulmonary congestion followed, forcing the decision to implant a biventricular assist device using centrifugal pumps. For the left side, surgeons used a 6-mm apical inflow cannula and a 6-mm arterial outflow cannula; for the right side, they placed a 14-Fr inflow cannula into the inferior vena cava via the right atrium and an 8-Fr outflow cannula into the distal pulmonary artery trunk, all secured with purse-string sutures.

What happened next is the technical heart of the report. The right ventricular assist device pumped roughly 900 mL/min, yet the left-sided pump could not function efficiently. The culprits were severe pulmonary hypertension and pulmonary regurgitation, which together prevented blood pushed into the pulmonary circulation from returning effectively to the left heart. In a decisive maneuver, the surgeons relocated the right-sided outflow cannula from the pulmonary artery into the left atrium, temporarily routing oxygenated blood directly to the left side of the heart and bypassing the obstructed pulmonary circuit. Left ventricular assist device flow stabilized at approximately 600 mL/min. The strategy bought time, but it carried trade-offs: left atrial cannulation raises the risk of systemic thromboembolism, and the circuit could not be disconnected from the artificial lung that oxygenates blood outside the body. The team therefore treated the configuration as a bridge within a bridge, to be dismantled as soon as the pulmonary vasculature could tolerate normal routing.

That evaluation came quickly. Cardiac catheterization on postoperative day 5, performed during temporary interruption of right-sided pumping, recorded a pulmonary artery pressure of 21/15 mmHg with a mean of 18 mmHg and a pulmonary vascular resistance index of 3.5 Wood units times meters squared, values indicating acceptable pulmonary vascular physiology. On postoperative day 13 the outflow cannula was moved back to the pulmonary artery trunk and the artificial lung was removed from the circuit. Bedside echocardiography then showed improving right ventricular contraction, but chest X-rays revealed progressing pulmonary congestion, which the surgeons attributed to excessive pulmonary blood flow generated by full right-sided support. Their response was a careful titration: right pump flow was gradually reduced to low-flow assistance. Throughout this period the left pump maintained a stable 900 mL/min flow and central venous pressure held near 12 mmHg even when right-sided support fell to 400 mL/min or was interrupted entirely, evidence that the native right ventricle and pulmonary circulation had recovered enough to fill the left pump on their own. Concerned about circuit thrombosis during prolonged low flow, the team removed the right ventricular assist device on postoperative day 20.

The recovery of other organs lagged behind the heart but eventually followed. Acute kidney and liver failure complicated the early postoperative course, requiring continuous hemodiafiltration from postoperative day 7. Bilirubin climbed as high as 15.1 mg/dL and renal dysfunction persisted for more than a month, but hemofiltration was discontinued on day 44, total bilirubin normalized on day 61, and the child was extubated on day 55. Only after these markers of end-organ recovery did the team secure in-house approval for heart transplant registration, the prerequisite under Japanese rules for implanting the Berlin Heart EXCOR, which was converted from the temporary centrifugal left ventricular assist device 76 days after the original biventricular implantation. The boy then remained stable on the pulsatile device for 374 days before undergoing successful heart transplantation, a total mechanical support journey of roughly 450 days from the first emergency pump to the donor heart.

The Osaka team frames the case within a strategy known as bridge to candidacy, an approach better documented in adults. In Japan, pediatric candidates face an average wait of 686 days for a donor heart, even though ten-year survival after pediatric transplantation reaches 96.2 percent, and by 2022 only 68 patients under 18 had ever been transplanted in the country. The Berlin Heart EXCOR has been approved there only since 2015 and only for patients already registered for transplantation, which creates a chicken-and-egg problem for infants whose comorbidities disqualify them from listing. Adult data show the workaround can succeed: large series report that short-term mechanical support can reverse refractory cardiogenic shock long enough for conversion to durable devices, with survival comparable to direct bridge-to-transplant pathways, though right ventricular support during the conversion emerges as a mortality risk factor. Pediatric evidence is thinner, but a Berlin group’s ten-year experience with 56 children and a multicenter United States study both suggest that prior extracorporeal support does not necessarily doom Berlin Heart outcomes, while low body weight, kidney and liver dysfunction, and biventricular support do worsen survival.

The case also contributes to a re-evaluation of Barth syndrome itself as a transplant indication. Because the condition combines heart failure with skeletal myopathy and immune compromise, patients were once considered unsuitable candidates, but after the first successful transplant in 1997, London investigators reported four successful cases, and a registry analysis of 43 transplanted Barth patients found outcomes for survival, infection, malignancy, and graft vasculopathy essentially equivalent to those of other recipients. The Osaka authors add an important caveat drawn from recent metabolic studies: transplantation does not fully normalize exercise tolerance, muscle mass, or substrate metabolism, because the underlying cardiolipin defect persists in skeletal muscle and other tissues. Their patient was not systematically assessed for these parameters after transplantation, a limitation the team acknowledges, and long-term multidisciplinary follow-up of neurodevelopment and metabolic status continues.

Beyond the individual rescue, the report is a detailed argument for staged, physiology-driven management of the failing right heart in small children. When pulmonary hypertension and valve regurgitation sabotage the left-sided pump, temporarily diverting right-sided outflow to the left atrium can stabilize the circulation; once catheterization confirms that pulmonary vascular resistance has fallen, rerouting to the pulmonary artery removes the thrombotic risk of left atrial cannulation and permits artificial lung removal, and stepwise flow reduction then tests whether the native right ventricle can carry the load. In this case that sequence converted a child in refractory cardiogenic shock with failing kidneys and liver into a registered transplant candidate with a durable device. The authors suggest the approach may extend the bridge-to-candidacy strategy to other high-risk pediatric patients with biventricular failure complicated by pulmonary hypertension, a population for whom waiting lists are long and options have historically been few.

Subject of Research: Bridge-to-candidacy mechanical circulatory support and heart transplantation in a pediatric patient with Barth syndrome-associated biventricular heart failure

Article Title: Successful bridge to heart transplantation in a pediatric patient with biventricular heart failure associated with Barth syndrome: a case report

Article References: Arita, K., Kido, T., Taira, M., Watanabe, T., Narita, J., Ishida, H., Ishii, R., Ueno, T., & Miyagawa, S. (2026). Successful bridge to heart transplantation in a pediatric patient with biventricular heart failure associated with Barth syndrome: a case report. Journal of Artificial Organs, 29(4), Article 60. https://doi.org/10.1007/s10047-026-01587-2

Image Credits: AI Generated

DOI: 10.1007/s10047-026-01587-2

Keywords: Barth syndrome, heart transplantation, ventricular assist device, Berlin Heart EXCOR, biventricular heart failure, pediatric cardiology, pulmonary hypertension, cardiogenic shock, mechanical circulatory support, TAZ gene, dilated cardiomyopathy, bridge to candidacy